Neurological Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting, 70780 [E6-20552]
Download as PDF
<![CDATA[
70780
Federal Register / Vol. 71, No. 234 / Wednesday, December 6, 2006 / Notices
experienced by citizens with
intellectual disabilities and their
families.
Dated: December 4, 2006.
Ericka Alston,
Executive Assistant to the Director,
President’s Committee for People with
Intellectual Disabilities.
[FR Doc. E6–20778 Filed 12–5–06; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Neurological Devices Panel of the
Medical Devices Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
PWALKER on PRODPC60 with NOTICES
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Neurological
Devices Panel of the Medical Devices
Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on January 26, 2007, from 8 a.m.
to 6 p.m.
Location: Hilton Washington, DC
North/Gaithersburg, Salons A, B, and C,
620 Perry Pkwy., Gaithersburg, MD.
Contact Person: Janet L. Scudiero,
Center for Devices and Radiological
Health (HFZ–410), Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 240–276–3737, or
FDA Advisory Committee Information
Line, 1–800–741–8138 (301–443–0572
in the Washington, DC area), code
3014512513. Please call the Information
Line for up-to-date information on this
meeting.
Agenda: The committee will discuss
and make recommendations on a
premarket notification application for a
device intended for the treatment of
major depressive disorder. The
committee will also hear and discuss
post approval study reports for two
recently approved neurological device
premarket approval applications. The
agency intends to make background
available to the public no later than 1
business day before the meeting. If FDA
is unable to post the background
material on its Web site prior to the
meeting, the background material will
VerDate Aug<31>2005
16:03 Dec 05, 2006
Jkt 211001
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on the agency Web site
after the meeting. Background material
is available at https://www.fda.gov/
ohrms/dockets/ac/acmenu.htm, click on
the year 2006 and scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before January 19, 2007.
Oral presentations from the public will
be scheduled for 30 minutes at the
beginning of the committee
deliberations and for 30 minutes near
the end of the committee deliberations.
Those desiring to make formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before January
11, 2007. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by January 12, 2006.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact AnnMarie
Williams, Conference Management
Staff, at 301–827–7291, at least 7 days
in advance of the meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: November 29, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and
Planning.
[FR Doc. E6–20552 Filed 12–5–06; 8:45 am]
BILLING CODE 4160–01–S
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Announcement of a Funding Priority
for Service Multiple Counties Under
the Fiscal Year 2007 New Access
Points in High Poverty Counties Grant
Opportunity
Health Resources and Services
Administration (HRSA), HHS
ACTION: Solicitation of comments.
AGENCY:
SUMMARY: The President’s Health Center
Initiative, which began in fiscal year
(FY) 2002, was established to
significantly impact 1,200 communities
by creating new or expanded health
center access points. Building on the
successes of this Initiative, a second
health center initiative has been
proposed by the President for FY 2007
to continue to increase access to high
quality comprehensive primary health
care for the most vulnerable populations
in the Nation. The goal of the
President’s new High Poverty Counties
Health Center Initiative is to increase
access to primary health care in 200 of
the Nation’s poorest counties that do not
have a health center. This new Initiative
is subject to the availability of funds in
the FY 2007 Health Center Program
appropriation.
The President’s High Poverty
Counties Health Center Initiative
contains two components, New Access
Point and Planning grants to be funded
under the Consolidated Health Center
Program, as authorized by section 330 of
the Public Health Service Act (42 U.S.C.
254b, as amended). New Access Point
grants will be made for the provision of
high quality comprehensive primary
and preventive health care services
through a new delivery site to a
designated medically underserved area
or population located in an eligible high
poverty county.
As part of the Initiative, it is
anticipated that the New Access Points
in High Poverty Counties grant
opportunity will contain a funding
priority. A funding priority is defined as
the favorable adjustment of combined
review scores of individually approved
applications when applications meet
specified criteria. The adjustment is
typically made by a set, pre-determined
number of points. For this grant
opportunity, a funding priority is
planned for applicants proposing to
serve multiple counties (i.e., the
proposed target population comes from
other county(ies) in addition to the
eligible high poverty county). Please
E:\FR\FM\06DEN1.SGM
06DEN1
]]>Agencies
[Federal Register Volume 71, Number 234 (Wednesday, December 6, 2006)]
[Notices]
[Page 70780]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-20552]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Neurological Devices Panel of the Medical Devices Advisory
Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Neurological Devices Panel of the Medical
Devices Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on January 26, 2007, from 8
a.m. to 6 p.m.
Location: Hilton Washington, DC North/Gaithersburg, Salons A, B,
and C, 620 Perry Pkwy., Gaithersburg, MD.
Contact Person: Janet L. Scudiero, Center for Devices and
Radiological Health (HFZ-410), Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850, 240-276-3737, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), code 3014512513. Please call the Information Line
for up-to-date information on this meeting.
Agenda: The committee will discuss and make recommendations on a
premarket notification application for a device intended for the
treatment of major depressive disorder. The committee will also hear
and discuss post approval study reports for two recently approved
neurological device premarket approval applications. The agency intends
to make background available to the public no later than 1 business day
before the meeting. If FDA is unable to post the background material on
its Web site prior to the meeting, the background material will be made
publicly available at the location of the advisory committee meeting,
and the background material will be posted on the agency Web site after
the meeting. Background material is available at https://www.fda.gov/
ohrms/dockets/ac/acmenu.htm, click on the year 2006 and scroll down to
the appropriate advisory committee link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
January 19, 2007. Oral presentations from the public will be scheduled
for 30 minutes at the beginning of the committee deliberations and for
30 minutes near the end of the committee deliberations. Those desiring
to make formal oral presentations should notify the contact person and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation on or before January 11, 2007. Time allotted
for each presentation may be limited. If the number of registrants
requesting to speak is greater than can be reasonably accommodated
during the scheduled open public hearing session, FDA may conduct a
lottery to determine the speakers for the scheduled open public hearing
session. The contact person will notify interested persons regarding
their request to speak by January 12, 2006.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact AnnMarie Williams,
Conference Management Staff, at 301-827-7291, at least 7 days in
advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: November 29, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and Planning.
[FR Doc. E6-20552 Filed 12-5-06; 8:45 am]
BILLING CODE 4160-01-S
